Institute of Neuropathology, University of Bonn Medical Center, Bonn, Germany.
Department of Neuropathology, Sainte-Anne Hospital and Paris Descartes University, Paris, France.
Brain Pathol. 2019 Mar;29(2):205-216. doi: 10.1111/bpa.12659. Epub 2018 Nov 11.
Ependymoma with YAP1-MAMLD1 fusion is a rare, recently described supratentorial neoplasm of childhood, with few cases published so far. We report on 15 pediatric patients with ependymomas carrying YAP1-MAMLD1 fusions, with their characteristic histopathology, immunophenotype and molecular/cytogenetic, radiological and clinical features. The YAP1-MAMLD1 fusion was documented by RT-PCR/Sanger sequencing, and tumor genomes were studied by molecular inversion probe (MIP) analysis. Significant copy number alterations were identified by GISTIC (Genomic Identification of Significant Targets in Cancer) analysis. All cases showed similar histopathological features including areas of high cellularity, presence of perivascular pseudo-rosettes, small to medium-sized nuclei with characteristic granular chromatin and strikingly abundant cells with dot-like cytoplasmic expression of epithelial membrane antigen. Eleven cases presented features of anaplasia, corresponding to WHO grade III. MRI showed large supratentorial multinodular tumors with cystic components, heterogeneous contrast enhancement, located in the ventricular or periventricular region. One of two variants of YAP1-MAMLD1 fusions was detected in all cases. The MIP genome profiles showed balanced profiles, with focal alterations of the YAP1 locus at 11q22.1-11q21.2 (7/14), MAMLD1 locus (Xp28) (10/14) and losses of chromosome arm 22q (5/14). Most patients were female (13/15) and younger than 3 years at diagnosis (12/15; median age, 8.2 months). Apart from one patient who died during surgery, all patients are alive without evidence of disease progression after receiving different treatment protocols, three without postoperative further treatment (median follow-up, 4.84 years). In this to date, largest series of ependymomas with YAP1-MAMLD1 fusions we show that they harbor characteristic histopathological, cytogenetic and imaging features, occur mostly in young girls under 3 years and are associated with good outcome. Therefore, this genetically defined neoplasm should be considered a distinct disease entity. The diagnosis should be confirmed by demonstration of the specific fusion. Further studies on large collaborative series are warranted to confirm our findings.
具有 YAP1-MAMLD1 融合的室管膜瘤是一种罕见的、最近描述的儿童幕上肿瘤,迄今为止发表的病例较少。我们报告了 15 例携带 YAP1-MAMLD1 融合的儿童室管膜瘤患者,其具有特征性的组织病理学、免疫表型以及分子/细胞遗传学、影像学和临床特征。通过 RT-PCR/Sanger 测序证实了 YAP1-MAMLD1 融合,通过分子倒置探针 (MIP) 分析研究了肿瘤基因组。通过 GISTIC(癌症中显著靶基因的基因组鉴定)分析确定了显著的拷贝数改变。所有病例均表现出相似的组织病理学特征,包括高细胞区、血管周围假玫瑰结、小至中等大小的核,具有特征性颗粒状染色质,以及大量细胞质点状表达上皮膜抗原的细胞。11 例表现为间变特征,对应于 WHO 分级 III 级。MRI 显示大型幕上多结节性肿瘤,伴有囊性成分,不均匀对比增强,位于脑室或脑室周围区域。所有病例均检测到 YAP1-MAMLD1 融合的两种变体之一。MIP 基因组谱显示平衡谱,YAP1 基因座(11q22.1-11q21.2)(7/14)、MAMLD1 基因座(Xp28)(10/14)和 22q 染色体臂缺失(5/14)存在局灶性改变。大多数患者为女性(13/15),诊断时年龄小于 3 岁(12/15;中位年龄,8.2 个月)。除 1 例患者在手术期间死亡外,所有患者均存活,且在接受不同治疗方案后未出现疾病进展的证据,3 例患者术后未进一步治疗(中位随访时间,4.84 年)。在迄今为止最大的 YAP1-MAMLD1 融合室管膜瘤系列中,我们表明它们具有特征性的组织病理学、细胞遗传学和影像学特征,主要发生在 3 岁以下的年轻女孩中,与良好的预后相关。因此,这种基因定义的肿瘤应被视为一种独特的疾病实体。应通过证实特定融合来确认诊断。需要进一步的大型协作系列研究来证实我们的发现。